Article Image

IPFS News Link • Corruption

Moderna Paid Fauci Lead Organization $400 Million in 'Royalties' on COVID-19 Vaccine Sales


The "catch-up-payment" that Moderna recently paid the NIAID was reported by the industry watchdog group Fierce Pharma as well as by the New York Times.

"In Moderna's earnings release Thursday, the company said it recently paid the National Institute of Allergy and Infectious Diseases (NIAID) a $400 million 'catch-up payment' under a new royalty-bearing license agreement between the parties," Fierce Pharma noted.

"The payment is part of a license agreement between Moderna and NIAID inked late last year. With the deal, Moderna is paying the U.S. government to access 'certain patent rights concerning stabilizing prefusion coronavirus spike proteins,'" the report added, citing Moderna Chief Financial Officer Jamie Mock.

Moderna agreed to pay NIAID "low single-digit royalties" on COVID-19 vaccine sales moving forward, Mock added.

As the report adds, "this agreement does not put Moderna out of the woods on the patent litigation front. Even after this deal, the vaccine maker is fighting with the U.S. National Institutes of Health over the origins of the core technology in the vaccine," The New York Times points out.